Kaiting Yang’s practice focuses on initial public offerings and other equity capital markets transactions on the Hong Kong Stock Exchange, pre-IPO investments, public takeovers and listing rules and securities regulations compliance. Kaiting has actively participated in pre-IPO financing and initial public offering of biotech company seeking to list on the HKEX, and regulatory compliance for biotech company listed on the HKEX, in particular, Ascletis Pharma Inc. (HKEX: 1672), the first pre-revenue biotech company listed on the HKEX under the new listing regime for companies from emerging and innovative sectors.

Download full bio 


  • Huitongda Network – HK$2.2 Billion IPO 

  • Asymchem Laboratories – HK$7.15 Billion IPO 

  • Keymed Biosciences – HK$3.1 Billion IPO 


  • Northwestern University Pritzker School of Law
    LLM, 2017

  • The University of Hong Kong
    MCL, 2014

  • Shenzhen University
    LLB, 2013

Admissions & Credentials

New York